Ascentage Pharma Group International American Depository Shares (AAPG) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ultragenyx Pharmaceutical (RARE) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, losing 50.5% versus a loss of 63.8%. Ultragenyx Pharmaceutical is the larger company by market cap ($1.53 billion vs $1.38 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | RARE |
|---|---|---|
| Share price | $14.75 | $15.48 |
| Market cap | $1.38B | $1.53B |
| 1-day change | +1.37% | +1.24% |
| YTD return | -44.55% | -33.52% |
| 1-year return | -63.83% | -50.45% |
| 5-year return | — | -80.89% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-2.26 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $673.00M |
| Revenue growth (YoY) | — | +20.18% |
| Net income (latest FY) | — | $-575.00M |
| Operating margin | — | -79.49% |
| Net margin | — | -85.44% |
| 52-week high | $37.50 | $39.89 |
| 52-week low | $14.46 | $12.73 |
| Distance from 52-week high | -60.67% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +219.53% | +81.20% |
| Average volume | 6.37K | 3.87M |
| Shares outstanding | 93.39M | 98.59M |
| Employees | 828 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RARE has outperformed AAPG by 13.4 percentage points over the past year.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
AAPG vs RARE FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.53B compared with $1.38B for Ascentage Pharma Group International American Depository Shares (AAPG).
Which stock has performed better over the past year, AAPG or RARE?
RARE returned -50.45% over the past 12 months, compared with -63.83% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.